Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal

Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it rights to a therapy for inflammatory bowel disease and potentially multiple other indications.

The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to acquire rights to develop and manufacture Telavant’s RVT-3101 drug candidate and commercialize it in the U.S. and in Japan.